Anmeldung erfolgt in Kürze...
Details werden geladen...
Entera Announces Second Quarter 2026 Financial Results and Business Updates | The Manila Times
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Ähnliche Seiten
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/06/tmt-newswire/globenewswire/monte-rosa-therapeutics-announces-second-quarter-2026-financial-results-and-business-updates/2399895Editas Medicine Announces Second Quarter 2026 Results and Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/06/tmt-newswire/globenewswire/editas-medicine-announces-second-quarter-2026-results-and-business-updates/2399337Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/07/tmt-newswire/globenewswire/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-business-updates/2400922Nanox Announces First Quarter 2026 Financial Results and Provides Business Updates | The Manila Times
https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/nanox-announces-first-quarter-2026-financial-results-and-provides-business-updates/2372821Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/06/tmt-newswire/globenewswire/climb-bio-reports-second-quarter-2026-financial-results-and-provides-business-updates/2399893